药明巨诺CAR-T药物有望进入商保目录，原价129万1针

Core Viewpoint - WuXi AppTec's CAR-T cell therapy, Rikeolunase injection, is making progress in negotiations to be included in the commercial insurance innovative drug directory, which is expected to reduce the financial burden on patients and benefit more individuals [1] Group 1 - Rikeolunase injection is the first domestically approved Class 1 CAR-T therapy in China [1] - The pricing for the therapy post-launch is set at 1.29 million yuan per injection [1]